These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 21054)

  • 41. Disopyramide pharmacokinetics in the elderly after single oral administration.
    Roberto P; Vitaliano B; Donatella P; Raffaella M; Sergio B; Gabriella C
    Pharmacol Res Commun; 1988 Dec; 20(12):1025-34. PubMed ID: 3211990
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Concentration-dependence of disopyramide binding to plasma protein and its influence on kinetics and dynamics.
    Lima JJ; Boudoulas H; Blanford M
    J Pharmacol Exp Ther; 1981 Dec; 219(3):741-7. PubMed ID: 7299695
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Disposition kinetics of disopyramide in human healthy volunteers described by an open three compartment model.
    Bonde J; Jensen NM; Pedersen LE; Angelo HR; Rasmussen SN; Trap-Jensen J; Kampmann JP
    Pharmacol Toxicol; 1989 May; 64(5):412-6. PubMed ID: 2771866
    [TBL] [Abstract][Full Text] [Related]  

  • 44. In vivo interaction of the enantiomers of disopyramide in human subjects.
    Giacomini KM; Nelson WL; Pershe RA; Valdivieso L; Turner-Tamiyasu K; Blaschke TF
    J Pharmacokinet Biopharm; 1986 Aug; 14(4):335-56. PubMed ID: 3772736
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of ethanol intake on disopyramide elimination by healthy volunteers.
    Olsen H; Bredesen JE; Lunde PK
    Eur J Clin Pharmacol; 1983; 25(1):103-5. PubMed ID: 6617710
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of altered disopyramide binding on its pharmacologic response in rabbits.
    Huang JD; Oie S
    J Pharmacol Exp Ther; 1982 Nov; 223(2):469-71. PubMed ID: 7131300
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Disopyramide in renal impairment.
    Whiting B; Elliott HL
    Lancet; 1977 Dec 24-31; 2(8052-8053):1363. PubMed ID: 74774
    [No Abstract]   [Full Text] [Related]  

  • 48. The effect of enzyme induction on the metabolism of disopyramide in man.
    Aitio ML; Mansury L; Tala E; Haataja M; Aitio A
    Br J Clin Pharmacol; 1981 Mar; 11(3):279-85. PubMed ID: 7213529
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Atenolol inhibits the elimination of disopyramide.
    Bonde J; Bødtker S; Angelo HR; Svendsen TL; Kampmann JP
    Eur J Clin Pharmacol; 1985; 28(1):41-3. PubMed ID: 3987784
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Disopyramide pharmacokinetics and metabolism: effect of inducers.
    Kapil RP; Axelson JE; Mansfield IL; Edwards DJ; McErlane B; Mason MA; Lalka D; Kerr CR
    Br J Clin Pharmacol; 1987 Dec; 24(6):781-91. PubMed ID: 3440098
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparative bioavailability of disopyramide after multiple dosing with standard capsules and controlled-release tablets.
    Forssell G; Graffner C; Nordlander R; Nyquist O
    Eur J Clin Pharmacol; 1980; 17(3):209-13. PubMed ID: 7363933
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Disopyramide pharmacokinetics and bioavailability.
    Dubetz DK; Brown NN; Hooper WD; Eadie MJ; Tyrer JH
    Br J Clin Pharmacol; 1978 Sep; 6(3):279-81. PubMed ID: 687507
    [No Abstract]   [Full Text] [Related]  

  • 53. Kinetics of disopyramide in decreased hepatic function.
    Bonde J; Graudal NA; Pedersen LE; Balsløv S; Angelo HR; Svendsen TL; Kampmann JP
    Eur J Clin Pharmacol; 1986; 31(1):73-7. PubMed ID: 3780831
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Disopyramide dialysability.
    Lancet; 1978 Jul; 2(8082):214. PubMed ID: 78419
    [No Abstract]   [Full Text] [Related]  

  • 55. Disopyramide: clinical indications, pharmacokinetics and laboratory assessment.
    Taylor EH; Pappas AA
    Ann Clin Lab Sci; 1986; 16(4):289-95. PubMed ID: 2427003
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Enhanced metabolism and diminished efficacy of disopyramide by enzyme induction?
    Aitio ML; Vuorenmaa T
    Br J Clin Pharmacol; 1980 Feb; 9(2):149-52. PubMed ID: 7356902
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Protein binding of disopyramide and elevated alpha-1-acid glycoprotein concentrations in serum obtained from dialysis patients and renal transplant recipients.
    Haughey DB; Kraft CJ; Matzke GR; Keane WF; Halstenson CE
    Am J Nephrol; 1985; 5(1):35-9. PubMed ID: 3881959
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Simultaneous determination of disopyramide and its mono-N-dealkyl metabolite in plasma and urine by high-performance liquid chromatography.
    Charette C; McGilveray IJ; Mainville C
    J Chromatogr; 1983 May; 274():219-30. PubMed ID: 6874823
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Quantitative analysis of the disopyramide concentration-effect relationship.
    Whiting B; Holford NH; Sheiner LB
    Br J Clin Pharmacol; 1980 Jan; 9(1):67-75. PubMed ID: 7356895
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Plasma concentrations and protein binding of disopyramide and mono-N-dealkyldisopyramide during chronic oral disopyramide therapy.
    Aitio ML
    Br J Clin Pharmacol; 1981 Apr; 11(4):369-75. PubMed ID: 7259930
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.